Literature DB >> 25390351

Expression of the chemokine receptor gene, CCR8, is associated With DUSP22 rearrangements in anaplastic large cell lymphoma.

Xiaoming Xing1, Thomas J Flotte, Mark E Law, Anthony J Blahnik, Wee-Joo Chng, Gaofeng Huang, Ryan A Knudson, Rhett P Ketterling, Julie C Porcher, Stephen M Ansell, Jagmohan Sidhu, Ahmet Dogan, Andrew L Feldman.   

Abstract

Anaplastic large cell lymphoma (ALCL) is one of the most common T-cell non-Hodgkin lymphomas and has 2 main subtypes: an anaplastic lymphoma kinase (ALK)-positive subtype characterized by ALK gene rearrangements and an ALK-negative subtype that is poorly understood. We recently identified recurrent rearrangements of the DUSP22 locus on 6p25.3 in both primary cutaneous and systemic ALK-negative ALCLs. This study aimed to determine the relationship between these rearrangements and expression of the chemokine receptor gene, CCR8. CCR8 has skin-homing properties and has been suggested to play a role in limiting extracutaneous spread of primary cutaneous ALCLs. However, overexpression of CCR8 has also been reported in systemic ALK-negative ALCLs. As available antibodies for CCR8 have shown lack of specificity, we examined CCR8 expression using quantitative real-time PCR in frozen tissue and RNA in situ hybridization (ISH) in paraffin tissue. Both approaches showed higher CCR8 expression in ALCLs with DUSP22 rearrangements than in nonrearranged cases (PCR: 19.5-fold increase, P=0.01; ISH: 3.3-fold increase, P=0.0008). CCR8 expression was not associated with cutaneous presentation, cutaneous biopsy site, or cutaneous involvement during the disease course. These findings suggest that CCR8 expression in ALCL is more closely related to the presence of DUSP22 rearrangements than to cutaneous involvement and that the function of CCR8 may extend beyond its skin-homing properties in this disease. This study also underscores the utility of RNA-ISH as a paraffin-based method for investigating gene expression when reliable antibodies for immunohistochemical analysis are not available.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25390351      PMCID: PMC4427553          DOI: 10.1097/PAI.0000000000000118

Source DB:  PubMed          Journal:  Appl Immunohistochem Mol Morphol        ISSN: 1533-4058


  26 in total

Review 1.  Chemokines in the systemic organization of immunity.

Authors:  Daniel J Campbell; Chang H Kim; Eugene C Butcher
Journal:  Immunol Rev       Date:  2003-10       Impact factor: 12.988

Review 2.  Pathobiology of ALK+ anaplastic large-cell lymphoma.

Authors:  Hesham M Amin; Raymond Lai
Journal:  Blood       Date:  2007-05-22       Impact factor: 22.113

3.  Primary and secondary cutaneous CD30(+) lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment.

Authors:  M W Bekkenk; F A Geelen; P C van Voorst Vader; F Heule; M L Geerts; W A van Vloten; C J Meijer; R Willemze
Journal:  Blood       Date:  2000-06-15       Impact factor: 22.113

4.  Demonstration of distinct antigenic profiles of small B-cell lymphomas by paraffin section immunohistochemistry.

Authors:  P J Kurtin; K S Hobday; S Ziesmer; B L Caron
Journal:  Am J Clin Pathol       Date:  1999-09       Impact factor: 2.493

5.  Molecular cloning and characterization of a novel dual specificity phosphatase, LMW-DSP2, that lacks the cdc25 homology domain.

Authors:  K Aoyama; M Nagata; K Oshima; T Matsuda; N Aoki
Journal:  J Biol Chem       Date:  2001-05-09       Impact factor: 5.157

6.  ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project.

Authors:  Kerry J Savage; Nancy Lee Harris; Julie M Vose; Fred Ullrich; Elaine S Jaffe; Joseph M Connors; Lisa Rimsza; Stefano A Pileri; Mukesh Chhanabhai; Randy D Gascoyne; James O Armitage; Dennis D Weisenburger
Journal:  Blood       Date:  2008-04-02       Impact factor: 22.113

7.  Cutaneous anaplastic large cell lymphoma and peripheral T-cell lymphoma NOS show distinct chromosomal alterations and differential expression of chemokine receptors and apoptosis regulators.

Authors:  Marloes S van Kester; Cornelis P Tensen; Maarten H Vermeer; Remco Dijkman; Aat A Mulder; Karoly Szuhai; Rein Willemze; Remco van Doorn
Journal:  J Invest Dermatol       Date:  2009-08-27       Impact factor: 8.551

8.  Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray.

Authors:  Christine P Hans; Dennis D Weisenburger; Timothy C Greiner; Randy D Gascoyne; Jan Delabie; German Ott; H Konrad Müller-Hermelink; Elias Campo; Rita M Braziel; Elaine S Jaffe; Zenggang Pan; Pedro Farinha; Lynette M Smith; Brunangelo Falini; Alison H Banham; Andreas Rosenwald; Louis M Staudt; Joseph M Connors; James O Armitage; Wing C Chan
Journal:  Blood       Date:  2003-09-22       Impact factor: 22.113

9.  Role of CCR8 and other chemokine pathways in the migration of monocyte-derived dendritic cells to lymph nodes.

Authors:  Chunfeng Qu; Emmerson W Edwards; Frank Tacke; Véronique Angeli; Jaime Llodrá; Guzman Sanchez-Schmitz; Alexandre Garin; Nasreen S Haque; Wendy Peters; Nico van Rooijen; Carmen Sanchez-Torres; Jonathan Bromberg; Israel F Charo; Steffen Jung; Sergio A Lira; Gwendalyn J Randolph
Journal:  J Exp Med       Date:  2004-11-08       Impact factor: 14.307

10.  Recurrent translocations involving the IRF4 oncogene locus in peripheral T-cell lymphomas.

Authors:  A L Feldman; M Law; E D Remstein; W R Macon; L A Erickson; K L Grogg; P J Kurtin; A Dogan
Journal:  Leukemia       Date:  2008-11-06       Impact factor: 11.528

View more
  7 in total

1.  Secondary cutaneous involvement by systemic anaplastic lymphoma kinase-negative anaplastic large-cell lymphoma with 6p25.3 rearrangement.

Authors:  Andrew L Feldman; Karen L Grogg; Ryan A Knudson; David J Inwards
Journal:  Histopathology       Date:  2015-06-19       Impact factor: 5.087

2.  Molecular profiling reveals immunogenic cues in anaplastic large cell lymphomas with DUSP22 rearrangements.

Authors:  Rebecca A Luchtel; Surendra Dasari; Naoki Oishi; Martin Bjerregård Pedersen; Guangzhen Hu; Karen L Rech; Rhett P Ketterling; Jagmohan Sidhu; Xueju Wang; Ryohei Katoh; Ahmet Dogan; N Sertac Kip; Julie M Cunningham; Zhifu Sun; Saurabh Baheti; Julie C Porcher; Jonathan W Said; Liuyan Jiang; Stephen Jacques Hamilton-Dutoit; Michael Boe Møller; Peter Nørgaard; N Nora Bennani; Wee-Joo Chng; Gaofeng Huang; Brian K Link; Fabio Facchetti; James R Cerhan; Francesco d'Amore; Stephen M Ansell; Andrew L Feldman
Journal:  Blood       Date:  2018-08-09       Impact factor: 22.113

3.  Genetics of anaplastic large cell lymphoma.

Authors:  Yu Zeng; Andrew L Feldman
Journal:  Leuk Lymphoma       Date:  2015-07-21

Review 4.  New developments in the pathology of malignant lymphoma: a review of the literature published from October 2014-December 2014.

Authors:  J Han van Krieken
Journal:  J Hematop       Date:  2015-03-07       Impact factor: 0.196

Review 5.  CD30-positive primary cutaneous lymphoproliferative disorders: molecular alterations and targeted therapies.

Authors:  Lucia Prieto-Torres; Socorro M Rodriguez-Pinilla; Arantza Onaindia; Mariano Ara; Luis Requena; Miguel Á Piris
Journal:  Haematologica       Date:  2019-01-10       Impact factor: 9.941

6.  JNK pathway-associated phosphatase associates with rheumatoid arthritis risk, disease activity, and its longitudinal elevation relates to etanercept treatment response.

Authors:  Li Sun; Jianxin Tu; Xiaowei Chen; Meijie Dai; Xiaoru Xia; Cailong Liu; Yan Zhou
Journal:  J Clin Lab Anal       Date:  2021-02-06       Impact factor: 2.352

Review 7.  IRF4 as an Oncogenic Master Transcription Factor.

Authors:  Regina Wan Ju Wong; Jolynn Zu Lin Ong; Madelaine Skolastika Theardy; Takaomi Sanda
Journal:  Cancers (Basel)       Date:  2022-09-02       Impact factor: 6.575

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.